For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
The Sunday Read: ‘What Does the U.S. Space Force Actually Do?’
Two Superpowers Walk Into a Garden
Biden’s Electric Car Problem
A Strategy to Treat Big Tech Like Big Tobacco
Hamas’s Bloody Arithmetic
The Doctors of Gaza
From Serial: ‘The Kids of Rutherford County’
What Adidas Knew About Kanye
The Supreme Court Tests Its Own Limits on Guns
The Trumps Take the Stand
The Growing Republican Battle Over War Funding
Swing State Voters Are Souring on Biden
The Sunday Read: ‘The Botched Hunt for the Gilgo Beach Killer’
1948
The Many Missed Warnings Before Maine’s Mass Shooting
Lessons From an Unending Conflict
A Historic Strike (And Win) For Auto Workers
Israel's Invasion Begins
The Sunday Read: ‘Who Hired the Hitmen to Silence Zitácuaro?’
A New Threat: Surprise Hurricanes
Create your
podcast in
minutes
It is Free
Up First
Post Reports
The Journal.
The Ezra Klein Show
Today, Explained